Review of the safety and efficacy of ustekinumab

Ellen J Scherl; Sheila Kumar; Ryan U Warren

doi:10.1177/1756283X10374216

Review of the safety and efficacy of ustekinumab

Therap Adv Gastroenterol. 2010 Sep;3(5):321-8. doi: 10.1177/1756283X10374216.

Authors

Ellen J Scherl¹, Sheila Kumar, Ryan U Warren

Affiliation

¹ Jill Roberts Associate Professor of Clinical Medicine and Director of Jill Roberts Center for Inflammatory Bowel Disease, Weill Medical College of Cornell University/New York Presbyterian Hospital, 425 East 61st Street, 10th Floor, New York, NY 10021, USA.

Abstract

Ustekinumab is a subcutaneously and intravenously administered fully human monoclonal immunoglobulin (IgG1) antibody targeting the interleukin (IL)-12/23 shared P40 subunit. The pivotal role of IL-12/23 inflammatory-mediated pathways is increasingly recognized in a plethora of immune-mediated inflammatory disorders including Crohn's disease, psoriasis, and multiple sclerosis. In a randomized controlled trial of ustekinumab in moderate-to-severe Crohn's disease, clinical response was achieved most notably in infliximab-experienced primary and secondary nonresponders and suboptimal responders.

Keywords: Crohn’s disease; anti-interleukin 12/23; antitumor necrosis factor; infliximab; primary nonresponder; secondary nonresponder; suboptimal infliximab response; ustekinumab.